Huntsman cancer utah trials

Search Patient Education. Contact Us. Get Involved. Search Jobs. Donate Now. About Total Cancer Care. Who can participate? You can be in this study if any of these are true: You have been diagnosed with any type of tumor or cancer.

Your family has a hereditary condition or strong history of cancer or tumors. You are a volunteer willing to share samples and data for research. Why should I take part? How do I participate? Same high-quality care. Learn More. Make an Appointment. Refer a Patient. Find a Doctor. Ask a Question. Find a Cancer Researcher. Search Patient Education. Contact Us. Get Involved. Search Jobs. Donate Now.

Our team is made up of: Medical, radiation, and surgery doctors Diagnostic specialists such as radiologists and pathologists Genetic counselors Nurses, dietitians, and social workers Our care teams include nurses, advanced care nurses, and physician assistants.

Learn more about HAC. Find a Leukemia Doctor. By Name By Location. Update Search. Counseling and administration of appropriate vaccinations Counseling and scheduling of other cancer screenings including skin cancer checks, colonoscopies, mammograms, and prostate cancer screenings.

As a patient, you will have the opportunity to donate your cancer cells to be used: In the lab to test new cancer drugs before they are used in people To discover genetic links in the transmission of CLL To research patterns of resistance to current therapy Learn more about clinical trials.

Your personal health habits, past illnesses, and symptoms help guide the exam. Laboratory tests: By testing body tissues, blood, urine, or other substances in the body, your health care team can check to see how the organs are functioning. They also look for abnormal amounts of blood cells. Bone marrow biopsy: The health care provider removes a small sample of bone marrow to look for abnormal cells under a microscope.

Stages of Chronic Lymphocytic Leukemia Staging is the process that shows if cancer has spread in the blood and bone marrow. Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN, which evaluated the effectiveness and safety of a new drug, apalutamide, to treat advanced prostate cancers.

In the largest study of its kind, more than half of patients with advanced prostate cancers appear to be strong candidates for targeted cancer therapies ET Leadership. See All Program Members.